Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma

This phase 1/2 trial evaluated the maximum tolerated doses, safety, and efficacy of pomalidomide, bortezomib, and dexamethasone (PVD) combination in patients with relapsed lenalidomide-refractory multiple myeloma (MM). In phase 1, dose level 1 consisted of pomalidomide (4 mg by mouth on days 1 to 21...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Paludo, Jonas, Mikhael, Joseph R., LaPlant, Betsy R., Halvorson, Alese E., Kumar, Shaji, Gertz, Morie A., Hayman, Suzanne R., Buadi, Francis K., Dispenzieri, Angela, Lust, John A., Kapoor, Prashant, Leung, Nelson, Russell, Stephen J., Dingli, David, Go, Ronald S., Lin, Yi, Gonsalves, Wilson I., Fonseca, Rafael, Bergsagel, P. Leif, Roy, Vivek, Sher, Taimur, Chanan-Khan, Asher A., Ailawadhi, Sikander, Stewart, A. Keith, Reeder, Craig B., Richardson, Paul G., Rajkumar, S. Vincent, Lacy, Martha Q.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2017
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5606008/
https://ncbi.nlm.nih.gov/pubmed/28684537
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-05-782961
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados